Abstract:Abstract Background High density lipoprotein (HDL) exerts various atheroprotective functions including cholesterol efflux capacity (CEC). HDL can attenuate lipid burden at atherosclerotic lesion by CEC. Based on the HDL`s role for moderate atherosclerosis, HDL-cholesterol level which indicates the amount of HDL has been evaluated to assess the risk of cardiovascular disease (CVD). Nevertheless, many clinical studies demonstrated that HDL-cholesterol level does not always reflect the risk of CVD, and CEC which represents the quality of HDL is considered as surrogate biomarker for CVD. CEC is prospective biomarker for CVD risk assessment, however, CEC measurement encounters barriers for clinical application because of its requirements of cultured cell and radioactive substance for conventional CEC assay. To overcome these problems, we invented a novel CEC assay called immobilized liposome-bound gel beads (ILG) method. This method is cell-free assay and utilizes a fluorescence substance as cholesterol tracer. Although the ILG method is useful assay for clinical application, previous study revealed that bilirubin caused false positive error on CEC value. Hence, current ILG method might produce incorrect CEC evaluation for patients with hyperbilirubinemia and even healthy subjects within the range of biological variation of bilirubin. In this study, we improved the influence of bilirubin for ILG method by using bilirubin oxidase (BOD). Methods BOD (Asahi Kasei Corp.) was added to 10 mM Tris-HCl (pH 7.4) containing 150 mM of NaCl and 1 mM of Na2EDTA (Buffer A). Bilirubin from ‘Interference check A Plus’ (Sysmex Inc.) was added to serum (free-: 10 mg/dL, conjugated-:9.7 mg/dL), and apoB-depleted serum (BDS) was derived from the bilirubin additive serum using polyethylene glycol. After the prepared bilirubin additive BDS was incubated with BOD-containing Buffer A for 16 h, the absorbance spectrum was analyzed. In addition, the time course of bilirubin decrement was monitored during 16 h-incubation. We further measured the fluorescence intensity of bilirubin additive BDS incubated with BOD-containing Buffer A. Using the newly developed BOD-containing Buffer A for ILG method, CEC of bilirubin additive serum was evaluated. Finally, we measured CEC of 4 healthy individuals by conventional and the improved ILG method. The CEC value was standardized by fluorescence intensity of reference sample which was measured in every assay. Results BOD contained in Buffer A could convert bilirubin to biliverdin from results of absorbance spectrum. According to the time course of bilirubin decrement, both free- and conjugated-bilirubin were oxidized to biliverdin in approximately 6 h. By converting bilirubin to biliverdin, fluorescence light was weakened greatly. We confirmed that there was no significant difference of CEC values between non bilirubin-additive serum and bilirubin additive serum. Compared healthy individual CEC values measured by conventional and improved ILG method, all subjects showed significant decrease of CEC values from the improved method, and false positive error caused by bilirubin was ameliorated. Conclusion In this study, we achieved to improve the positive error caused by bilirubin on CEC assay using ILG method. This improvement would contribute to more accurate CEC assessment by ILG method and advance the clinical application of this method.

The Impact of Bilirubin on 7- and 7-Hydroxysteroid Dehydrogenases: Spectra and Docking Analysis

The Impact of Bilirubin on 7Α- and 7Β-Hydroxysteroid Dehydrogenases: Spectra and Docking Analysis

The Regulatory Implications of Hydroquinone for the Multifunctional Enzyme Dehaloperoxidase-Hemoglobin from Amphitrite Ornata

Engineering the Cofactor Binding Site of 7Α-Hydroxysteroid Dehydrogenase for Improvement of Catalytic Activity, Thermostability, and Alteration of Substrate Preference.

Analysis of interactions of bilirubin and cyclodextrin by docking and molecular dynamics

Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity

A Novel 7Α-Hydroxysteroid Dehydrogenase: Magnesium Ion Significantly Enhances Its Activity and Thermostability.

A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

Bilirubin is a new ligand for nuclear receptor Liver Receptor Homolog-1.

The Antagonistic Effect of Bilirubin Against the m-DNB Induced Oxidative Stress,DNA Damage and Synthesis Inhibition in Primary Culture Rat Hepatocyte

Unconjugated bilirubin promotes uric acid restoration by activating hepatic AMPK pathway

An Overview of 7- and 7-Hydroxysteroid Dehydrogenases: Structure, Specificity and Practical Application

Simultaneous Determination of Bilirubin and Its Glucuronides in Liver Microsomes and Recombinant UGT1A1 Enzyme Incubation Systems by HPLC Method and Its Application to Bilirubin Glucuronidation Studies

Influence of conformation and intramolecular hydrogen bonding on the acyl glucuronidation and biliary excretion of acetylenic bis-dipyrrinones related to bilirubin

An Overview of 7Α- and 7Β-Hydroxysteroid Dehydrogenases: Structure, Specificity and Practical Application

Bilirubin as a signaling molecule

Bilirubin neurotoxicity is associated with proteasome inhibition

Value of Bilirubin Oxidase and Its Mutants in the Diagnosis of Hyperbilirubinemia.

Characterization of a Novel Thermostable 7α-Hydroxysteroid Dehydrogenase

CYP8B1 Catalyzes 12alpha-Hydroxylation of C27 Bile Acid: In Vitro Conversion of Dihydroxycoprostanic Acid into Trihydroxycoprostanic Acid

Bilirubin participates in protecting of heme oxygenase-1 induction by quercetin against ethanol hepatotoxicity in cultured rat hepatocytes.